11
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Soluble Interleukin-6 Receptor in the COVID-19 Cytokine Storm Syndrome

      news

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Data suggest that interleukin (IL)-6 blockade could reduce mortality in severe COVID-19, yet IL-6 is only modestly elevated in most patients. Chen et al. describe the role of soluble interleukin-6 receptor (sIL-6R) in IL-6 trans-signaling, and how understanding the IL-6:sIL-6R axis might help define and treat COVID-19 cytokine storm syndrome.

          Related collections

          Author and article information

          Journal
          Cell Rep Med
          Cell Rep Med
          Cell Reports Medicine
          The Author(s).
          2666-3791
          19 April 2021
          19 April 2021
          : 100269
          Affiliations
          [1 ]Division of Hematology, University of British Columbia, Vancouver, BC, V5Z1M9, Canada
          [2 ]Centre for Health Education Scholarship, University of British Columbia, Vancouver, BC, V6T1Z3, Vancouver, Canada
          [3 ]Division of Allergy and Immunology, University of British Columbia, Vancouver, BC, V5Z1M9, Canada
          [4 ]Division of Rheumatology, University of British Columbia, Vancouver, BC, V5Z1M9, Canada
          [5 ]Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V5Z1M9, Canada
          [6 ]Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, V6T1Z3, Canada
          [7 ]Division of Critical Care Medicine, University of British Columbia, Vancouver, BC, V5Z1M9, Canada
          Author notes
          []Correspondence to: (Lead Contact) Luke Y.C. Chen, 2775 Laurel St, 10th Floor, Vancouver General Hospital, Vancouver, BC, V5Z1M9, Canada; tel: 6048755270; fax: 6048754763;
          Article
          S2666-3791(21)00091-4 100269
          10.1016/j.xcrm.2021.100269
          8055165
          33899032
          87a30924-40a8-4236-a1b6-02d6adebede8
          © 2021 The Author(s)

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          Categories
          Commentary

          cytokine storm,covid-19,interleukin-6,interleukin-6 receptor,tocilizumab,threshold concept

          Comments

          Comment on this article